Compare · ARGX vs CERO
ARGX vs CERO
Side-by-side comparison of argenx SE (ARGX) and CERo Therapeutics Holdings Inc. (CERO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and CERO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX carries a market cap of $50.47B.
- ARGX has been more active in the news (6 items in the past 4 weeks vs 5 for CERO).
- ARGX has more recent analyst coverage (25 ratings vs 1 for CERO).
- Company
- argenx SE
- CERo Therapeutics Holdings Inc.
- Price
- $812.95+1.32%
- $0.10-94.51%
- Market cap
- $50.47B
- -
- 1M return
- +0.24%
- -
- 1Y return
- +41.53%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 6
- 5
- Recent ratings
- 25
- 1
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest CERO
- SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
- CERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
- SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
- SEC Form 10-Q filed by CERo Therapeutics Holdings Inc.
- CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
- SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
- CERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
- SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
- Amendment: SEC Form 10-K/A filed by CERo Therapeutics Holdings Inc.
- SEC Form 4 filed by Francois Eric